Get the Stockscreener App
3.22
3.88%
-0.13
After Hours:
3.22
Cellectar Biosciences Inc stock is traded at $3.22, with a volume of 97,695.
It is down -3.88% in the last 24 hours and down -14.59% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$3.35
Open:
$3.39
24h Volume:
97,695
Relative Volume:
0.64
Market Cap:
$13.65M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.9908
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
+17.52%
1M Performance:
-14.59%
6M Performance:
-32.92%
1Y Performance:
+820.26%
1-Day Range:
$3.145
$3.65
1-Week Range:
$2.70
$3.72
52-Week Range:
$0.2298
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.22 | 14.20M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Trade Report: Why Rezolve AI PLC stock appeals to dividend seekersWeekly Trading Summary & Fast Momentum Entry Tips - moha.gov.vn
What drives Cellectar Biosciences Inc stock priceHealthcare Stock Analysis & Affordable Growth Trading - earlytimes.in
Targets Report: Why retail investors favor Cellectar Biosciences Inc stockMarket Growth Review & Accurate Entry/Exit Alerts - moha.gov.vn
Layoff Watch: Will Cellectar Biosciences Inc stock outperform value stocksBond Market & Community Verified Trade Signals - moha.gov.vn
Can Ahimsa Industries Limited Regain Momentum After BreakdownMarket Rumors and News & Affordable Stock Market Tips - earlytimes.in
Will Cellectar Biosciences Inc. stock reach Wall Street targets2025 Investor Takeaways & Real-Time Volume Spike Alerts - Улправда
Why Cellectar Biosciences Inc. stock could rally in 2025July 2025 Reactions & Weekly Top Stock Performers List - Улправда
How Cellectar Biosciences Inc. (NV4) stock reacts to weak economyJuly 2025 WrapUp & Smart Allocation Stock Reports - Bölüm Sonu Canavarı
Will Cellectar Biosciences Inc. stock benefit from sector rotation2025 Stock Rankings & Low Volatility Stock Suggestions - Улправда
Why Cellectar Biosciences Inc. stock remains undervaluedJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Aug Swings: Will Cellectar Biosciences Inc. stock reach Wall Street targets2025 Historical Comparison & Weekly Watchlist of Top Performers - ulpravda.ru
How Cellectar Biosciences Inc. stock trades before earningsJuly 2025 Volume & Low Risk Entry Point Tips - Улправда
Is Cellectar Biosciences Inc. stock a buy before product launchesEarnings Growth Report & Real-Time Volume Surge Alerts - DonanımHaber
Should I buy Cellectar Biosciences Inc. (NV4) stock before earnings seasonJuly 2025 Update & Real-Time Market Trend Scan - DonanımHaber
Why retail investors favor Cellectar Biosciences Inc. stockQuarterly Market Summary & Smart Swing Trading Alerts - DonanımHaber
What MACD trends signal for Cellectar Biosciences Inc. (NV4) stock2025 Short Interest & Verified Momentum Stock Alerts - Улправда
Bond Watch: Why Cellectar Biosciences Inc. stock could rally in 2025July 2025 Setups & Momentum Based Trading Ideas - Улправда
Is Cellectar Biosciences Inc. stock dividend yield sustainableMarket Performance Summary & Advanced Swing Trade Entry Plans - Улправда
Cellectar Biosciences announces supply agreement with Ionetix - MSN
Cellectar Biosciences, Inc. (CLRB) director John Neis reports stock sale - Stock Titan
Cellectar secures multi-year supply of alpha-emitting radioisotopes By Investing.com - Investing.com Australia
Cellectar Biosciences : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Cellectar Biosciences announces strategic supply agreement with Ionetix - marketscreener.com
Cellectar Biosciences (CLRB) Secures Supply Agreement for Radioi - GuruFocus
Cellectar secures multi-year supply of alpha-emitting radioisotopes - Investing.com
Cellectar Biosciences Announces Multi-Year Supply Agreement with Ionetix for Alpha-Emitting Radioisotopes - Quiver Quantitative
Cellectar Biosciences IncAnnounces Multi-Y - 富途牛牛
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies - GlobeNewswire
Cellectar Biosciences Earnings Notes - Trefis
MACD Signal: How Cellectar Biosciences Inc NV4 stock performs in easing cyclesRate Hike & Smart Money Movement Tracker - moha.gov.vn
Marginal Zone Lymphoma Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight - The Globe and Mail
Cellectar Biosciences (CLRB) price target decreased by 44.05% to 47.94 - MSN
Can Cellectar Biosciences Inc. (NV4) stock retain market dominance2025 Top Decliners & Proven Capital Preservation Methods - Newser
Will Cellectar Biosciences Inc. (NV4) stock deliver compounding returnsWeekly Trend Summary & Advanced Swing Trade Entry Alerts - Newser
Will Cellectar Biosciences Inc. (NV4) stock maintain strong growthJuly 2025 Price Swings & Verified Trade Idea Suggestions - Newser
Is Cellectar Biosciences Inc. (NV4) stock supported by strong fundamentalsPrice Action & High Accuracy Trade Alerts - Newser
How reliable is Cellectar Biosciences Inc. (NV4) stock dividend growthDip Buying & Stock Portfolio Risk Management - Newser
Cellectar Biosciences (CLRB) Stock Analysis Report | Financials & Insights - Benzinga
Why retail investors pile into Cellectar Biosciences Inc. stockGap Down & Advanced Swing Trade Entry Alerts - Newser
Critical Analysis: Cellectar Biosciences (NASDAQ:CLRB) & Agilent Technologies (NYSE:A) - Defense World
How strong is Cellectar Biosciences Inc. (NV4) stock earnings growthEarnings Overview Summary & Weekly Top Stock Performers List - Newser
Is Cellectar Biosciences Inc. stock attractive for ETFs2025 Major Catalysts & Verified High Yield Trade Plans - Newser
Cellectar Biosciences sees cash balance sufficient into 2Q25 - TipRanks
Cellectar Biosciences Reports Q3 2025 Financial Progress - MSN
Is Cellectar Biosciences Inc. stock near bottom after decline2025 Macro Impact & Breakout Confirmation Trade Signals - newser.com
CLRB warrants resale, going concern warning and WM drug milestones - Stock Titan
Is Cellectar Biosciences Inc. (NV4) stock a top dividend aristocrat candidate2025 Geopolitical Influence & Intraday High Probability Alerts - newser.com
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cellectar Biosciences Inc Stock (CLRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
11,638 |
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):